Cold Plasma-Treated Ringer's Saline: A Weapon to Target Osteosarcoma.
Ringer’s saline
bone cancer
cold atmospheric plasma
organotypic model
osteosarcoma
plasma-activated liquid
reactive species
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Jan 2020
17 Jan 2020
Historique:
received:
23
12
2019
revised:
10
01
2020
accepted:
14
01
2020
entrez:
23
1
2020
pubmed:
23
1
2020
medline:
23
1
2020
Statut:
epublish
Résumé
Osteosarcoma (OS) is the main primary bone cancer, presenting poor prognosis and difficult treatment. An innovative therapy may be found in cold plasmas, which show anti-cancer effects related to the generation of reactive oxygen and nitrogen species in liquids. In vitro models are based on the effects of plasma-treated culture media on cell cultures. However, effects of plasma-activated saline solutions with clinical application have not yet been explored in OS. The aim of this study is to obtain mechanistic insights on the action of plasma-activated Ringer's saline (PAR) for OS therapy in cell and organotypic cultures. To that aim, cold atmospheric plasma jets were used to obtain PAR, which produced cytotoxic effects in human OS cells (SaOS-2, MG-63, and U2-OS), related to the increasing concentration of reactive oxygen and nitrogen species generated. Proof of selectivity was found in the sustained viability of hBM-MSCs with the same treatments. Organotypic cultures of murine OS confirmed the time-dependent cytotoxicity observed in 2D. Histological analysis showed a decrease in proliferating cells (lower Ki-67 expression). It is shown that the selectivity of PAR is highly dependent on the concentrations of reactive species, being the differential intracellular reactive oxygen species increase and DNA damage between OS cells and hBM-MSCs key mediators for cell apoptosis.
Identifiants
pubmed: 31963398
pii: cancers12010227
doi: 10.3390/cancers12010227
pmc: PMC7017095
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Research Council
ID : 714793
Pays : International
Organisme : Ministerio de Economía y Competitividad
ID : MAT2015-65601-R
Organisme : Generalitat de Catalunya
ID : 2019 FI-B00479
Organisme : Generalitat de Catalunya
ID : 2017 SGR 1165
Références
Trends Biotechnol. 2018 Nov;36(11):1183-1198
pubmed: 30033340
Cell Rep. 2014 Apr 10;7(1):104-12
pubmed: 24703847
Skin Pharmacol Physiol. 2014;27(1):25-35
pubmed: 23921169
Redox Biol. 2019 Sep;26:101291
pubmed: 31421409
Arch Biochem Biophys. 2014 Nov 1;561:159-66
pubmed: 25046842
Sci Rep. 2017 Jun 30;7(1):4479
pubmed: 28667316
PLoS One. 2015 Aug 14;10(8):e0133120
pubmed: 26275141
Appl Microbiol Biotechnol. 2014;98(14):6205-13
pubmed: 24841116
Anticancer Agents Med Chem. 2018;18(6):824-831
pubmed: 29732979
Anticancer Res. 2016 Jan;36(1):221-9
pubmed: 26722047
Biointerphases. 2015 Jun 23;10(2):029510
pubmed: 25908593
J Biomed Biotechnol. 2011;2011:603925
pubmed: 21188172
Anticancer Res. 2016 Nov;36(11):5915-5922
pubmed: 27793916
J Vis Exp. 2019 Apr 12;(146):
pubmed: 31033963
Expert Rev Med Devices. 2013 May;10(3):367-77
pubmed: 23668708
Cancer Treat Rev. 2006 Oct;32(6):423-36
pubmed: 16860938
PLoS One. 2018 Oct 12;13(10):e0204916
pubmed: 30312292
Sci Rep. 2019 Nov 6;9(1):16160
pubmed: 31695110
Anticancer Res. 2017 Mar;37(3):1031-1038
pubmed: 28314261
Sci Rep. 2016 Feb 24;6:21464
pubmed: 26908060
Ther Adv Med Oncol. 2018 Jul 20;10:1758835918786475
pubmed: 30046358
Cancer Lett. 2017 Oct 1;405:90-99
pubmed: 28774797
Crit Rev Oncog. 2015;20(3-4):173-97
pubmed: 26349415
Anticancer Res. 2019 Jan;39(1):151-157
pubmed: 30591452
Oncotarget. 2016 May 31;7(22):32980-9
pubmed: 27145275
Free Radic Biol Med. 2017 Dec;113:36-47
pubmed: 28916476
PLoS One. 2015 Dec 14;10(12):e0144968
pubmed: 26661594
PLoS One. 2013 Nov 12;8(11):e79325
pubmed: 24265766
Sci Rep. 2016 Nov 08;6:36282
pubmed: 27824103
Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):
pubmed: 29158312
Int J Mol Sci. 2017 Sep 19;18(9):
pubmed: 28925941
Cancer Lett. 2015 Oct 10;367(1):18-25
pubmed: 26187782
Curr Opin Pharmacol. 2014 Jun;16:15-23
pubmed: 24632219
Mol Oncol. 2014 Sep 12;8(6):1095-111
pubmed: 25087573
Tissue Eng Part C Methods. 2017 Feb;23(2):72-85
pubmed: 28007011
PLoS One. 2011;6(10):e27064
pubmed: 22046445
Free Radic Biol Med. 2017 Sep;110:72-80
pubmed: 28571751
Oxid Med Cell Longev. 2017;2017:2467940
pubmed: 29123614
Semin Cell Dev Biol. 2018 Aug;80:50-64
pubmed: 28587975
Biochim Biophys Acta Gen Subj. 2019 Apr;1863(4):692-702
pubmed: 30690121
Nat Rev Cancer. 2014 Nov;14(11):722-35
pubmed: 25319867
Sci Rep. 2018 Oct 18;8(1):15418
pubmed: 30337623
Leuk Lymphoma. 2014 Feb;55(2):378-91
pubmed: 23566162
Wound Repair Regen. 2015 Nov-Dec;23(6):878-84
pubmed: 26342154
J Craniomaxillofac Surg. 2016 Sep;44(9):1445-52
pubmed: 27499516
Sci Rep. 2017 Nov 28;7(1):16478
pubmed: 29184131
Pharmacol Ther. 2013 Jan;137(1):89-99
pubmed: 22983152
Sci Rep. 2019 May 20;9(1):7583
pubmed: 31110227
J Cell Physiol. 2009 Dec;221(3):778-88
pubmed: 19746444
Pathol Res Pract. 2017 Jul;213(7):773-777
pubmed: 28554762
Anticancer Res. 2017 Oct;37(10):5407-5414
pubmed: 28982850
Nitric Oxide. 2019 Dec 1;93:102-114
pubmed: 31541733
Sci Rep. 2019 Jul 23;9(1):10681
pubmed: 31337843
In Vivo. 2002 Jul-Aug;16(4):223-8
pubmed: 12224130
Br J Cancer. 2015 Apr 28;112(9):1536-45
pubmed: 25839988
Biol Chem. 2018 Dec 19;400(1):39-62
pubmed: 30044757
Arch Biochem Biophys. 2018 Sep 15;654:136-145
pubmed: 30026027
Cancer Treat Res. 2009;152:3-13
pubmed: 20213383
Am J Physiol Regul Integr Comp Physiol. 2017 Dec 1;313(6):R646-R653
pubmed: 28835450
Cancers (Basel). 2017 May 30;9(6):
pubmed: 28555065